Biren Amin
Stock Analyst at Piper Sandler
(1.41)
# 3,427
Out of 4,908 analysts
62
Total ratings
41.82%
Success rate
-10.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Neutral | $32 → $18 | $12.76 | +41.07% | 9 | Jul 21, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $63 → $68 | $45.50 | +49.45% | 3 | Jul 14, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $1.66 | +262.54% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $0.88 | +354.60% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $6.13 | +177.32% | 2 | May 16, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $7 | $1.33 | +426.32% | 3 | May 14, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $38 → $51 | $33.31 | +53.11% | 1 | Apr 14, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $38 | $16.00 | +137.57% | 1 | Mar 31, 2025 | |
| ELEV Elevation Oncology | Downgrades: Neutral | $10 → $0.7 | $0.38 | +86.67% | 2 | Mar 21, 2025 | |
| MNPR Monopar Therapeutics | Assumes: Overweight | $76 | $45.52 | +66.96% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $3.01 | +298.67% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $31.94 | +122.33% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $4 | $4.43 | -9.71% | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $8.71 | +301.84% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $10.68 | +96.63% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $67.42 | +70.57% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $19.47 | +64.36% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $5.93 | -49.37% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $11.52 | +30.21% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.39 | +4,935.97% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.35 | +14,409.25% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.26 | +356.27% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.37 | +1,334.60% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $5.80 | +8,520.69% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.85 | +139.15% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $560.58 | +23.27% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $2.35 | +325.53% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $26.01 | +288.31% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $132.59 | -47.96% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $467.20 | -66.82% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $1.99 | +6,724.23% | 4 | Mar 6, 2017 |
Sarepta Therapeutics
Jul 21, 2025
Maintains: Neutral
Price Target: $32 → $18
Current: $12.76
Upside: +41.07%
BridgeBio Pharma
Jul 14, 2025
Maintains: Overweight
Price Target: $63 → $68
Current: $45.50
Upside: +49.45%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $1.66
Upside: +262.54%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $0.88
Upside: +354.60%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $6.13
Upside: +177.32%
Allogene Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.33
Upside: +426.32%
LENZ Therapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $38 → $51
Current: $33.31
Upside: +53.11%
Centessa Pharmaceuticals
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $16.00
Upside: +137.57%
Elevation Oncology
Mar 21, 2025
Downgrades: Neutral
Price Target: $10 → $0.7
Current: $0.38
Upside: +86.67%
Monopar Therapeutics
Mar 19, 2025
Assumes: Overweight
Price Target: $76
Current: $45.52
Upside: +66.96%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $3.01
Upside: +298.67%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $31.94
Upside: +122.33%
Jan 30, 2025
Downgrades: Neutral
Price Target: $34 → $4
Current: $4.43
Upside: -9.71%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $8.71
Upside: +301.84%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $10.68
Upside: +96.63%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $67.42
Upside: +70.57%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $19.47
Upside: +64.36%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $5.93
Upside: -49.37%
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $11.52
Upside: +30.21%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.39
Upside: +4,935.97%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.35
Upside: +14,409.25%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.26
Upside: +356.27%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $2.37
Upside: +1,334.60%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $5.80
Upside: +8,520.69%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $5.85
Upside: +139.15%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $560.58
Upside: +23.27%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $2.35
Upside: +325.53%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $26.01
Upside: +288.31%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $132.59
Upside: -47.96%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $467.20
Upside: -66.82%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $1.99
Upside: +6,724.23%